Circulation Research · 2024 · 19 citations · 83 references
Veterinary MedicineImmunologyPathobiologyInflammationInnate ImmunityMolecular ImmunologyAnti-inflammatory PharmacologyChronic InflammationInflammatory Cell ResponsesInflammatory SignalingResolution Of InflammationSingle-cell TranscriptomicsAnti-inflammatory ActivityAnti-inflammatory TherapeuticsAtherosclerosis Molecular MechanismsChronic Inflammation ResolutionLow-grade Chronic InflammationMonocyte BiologyPrecision TherapeuticsSingle-cell Rna Sequencing
BACKGROUND: Chronic inflammation initiated by inflammatory monocytes underlies the pathogenesis of atherosclerosis. However, approaches that can effectively resolve chronic low-grade inflammation targeting monocytes are not readily available. The small chemical compound 4-phenylbutyric acid (4-PBA) exhibits broad anti-inflammatory effects in reducing atherosclerosis. Selective delivery of 4-PBA reprogrammed monocytes may hold novel potential in providing targeted and precision therapeutics for the treatment of atherosclerosis. METHODS: Systems analyses integrating single-cell RNA sequencing and complementary immunologic approaches characterized key resolving characteristics as well as defining markers of reprogrammed monocytes trained by 4-PBA. Molecular mechanisms responsible for monocyte reprogramming were assessed by integrated biochemical and genetic approaches. The intercellular propagation of homeostasis resolution was evaluated by coculture assays with donor monocytes trained by 4-PBA and recipient naive monocytes. The in vivo effects of monocyte resolution and atherosclerosis prevention by 4-PBA were assessed with the high-fat diet-fed ApoE −/− mouse model with IP 4-PBA administration. Furthermore, the selective efficacy of 4-PBA-trained monocytes was examined by IV transfusion of ex vivo trained monocytes by 4-PBA into recipient high-fat diet-fed ApoE −/− mice. RESULTS: In this study, we found that monocytes can be potently reprogrammed by 4-PBA into an immune-resolving state characterized by reduced adhesion and enhanced expression of anti-inflammatory mediator CD24. Mechanistically, 4-PBA reduced the expression of ICAM-1 (intercellular adhesion molecule 1) via reducing peroxisome stress and attenuating SYK (spleen tyrosine kinase)-mTOR (mammalian target of rapamycin) signaling. Concurrently, 4-PBA enhanced the expression of resolving mediator CD24 through promoting PPARγ (peroxisome proliferator-activated receptor γ) neddylation mediated by TOLLIP (toll-interacting protein). 4-PBA-trained monocytes can effectively propagate anti-inflammation activity to neighboring monocytes through CD24. Our data further demonstrated that 4-PBA-trained monocytes effectively reduce atherosclerosis pathogenesis when administered in vivo. CONCLUSIONS: Our study describes a robust and effective approach to generate resolving monocytes, characterizes novel mechanisms for targeted monocyte reprogramming, and offers a precision therapeutics for atherosclerosis based on delivering reprogrammed resolving monocytes.
83
Kensuke Inaba, Muneo Inaba, Nikolaus Romani et al. · The Journal of Experimental Medicine · 1992 · 3.8K citations · Full text
TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-β
Jonathan C. Kagan, Tian Su, Tiffany Horng et al. · Nature Immunology · 2008 · 1.2K citations
Peroxisomes Are Signaling Platforms for Antiviral Innate Immunity
Evelyn Dixit, Steeve Boulant, Yijing Zhang et al. · Cell · 2010 · 814 citations · Full text
CD24 and Siglec-10 Selectively Repress Tissue Damage–Induced Immune Responses
Guo‐Yun Chen, Jie Tang, Pan Zheng et al. · Science · 2009 · 777 citations · Full text